Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Medicenna Therapeutics Corp. MDNA
$0.70
-$0.05 (-7.64%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
53189126.00000000
-
week52high
1.88
-
week52low
0.40
-
Revenue
0
-
P/E TTM
-7
-
Beta
0.52812800
-
EPS
-0.14000000
-
Last Dividend
0.00000000
-
Next Earnings Date
20 июн 2023 г. в 12:30
Описание компании
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | 18 дек 2020 г. | |
| Oppenheimer | Outperform | 17 дек 2020 г. | |
| HC Wainwright & Co. | Buy | 25 ноя 2020 г. | |
| HC Wainwright & Co. | Buy | 10 сент 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Medicenna to Present at the 2023 Guggenheim Oncology Conference
GlobeNewsWire
31 янв 2023 г. в 07:30
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023.
Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023
GlobeNewsWire
26 янв 2023 г. в 07:00
TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights.
Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q2 2023 Earnings Call Transcript
Seeking Alpha
04 ноя 2022 г. в 15:25
Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q2 2023 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants David Martin - Bloom Burton Catherine Novack - Jones Search Operator Hello and welcome to the Medicenna Therapeutics' Fiscal Second Quarter Earnings Call. All participants are in a listen-only mode.
Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022
GlobeNewsWire
25 окт 2022 г. в 07:00
TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, 2022 at 8:30 AM ET to report its second quarter fiscal 2023 financial results and operational highlights.
2 ‘strong buy' penny stocks with over 300% possible upside
Finbold
19 авг 2022 г. в 04:28
Penny stocks are shares usually below $5, representing small companies, most of which trade by over-the-counter (OTC) transactions, while there